This symposium, presented at ACMG 2025, summarizes the APHENITY study which assessed the effectiveness of sepiapterin on dietary Phe in a broad population of phenylketonuria (PKU) patients, and discusses the need for innovative treatment approaches
All congress activities
International congresses, conferences and meetings offer the opportunity to share data and drive discussion that can progress the management of conditions such as phenylketonuria (PKU). Access our content from recent congresses and society meetings here.
|
Congress
Topic
Type
Year
This symposium, presented at ICIEM 2025, provides an overview of sepiapterin as a treatment for phenylketonuria (PKU) and the current PKU disease landscape
This poster, presented at ACMG 2025, describes interim results from the ongoing APHENITY extension study, which evaluated the effect of sepiapterin on dietary Phe tolerance in a broad population of phenylketonuria (PKU) participants
This symposium, presented at SSEIM 2024, provides an overview of sepiapterin as a potential treatment for phenylketonuria (PKU) and its implications for patient management
▼ Sepiapterin is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-PTC923-2500012 | September 2025
MED-ALL-PKU-2500224 | October 2025